(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2013 (14.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/169746 A3

(51) International Patent Classification:
A61K 31/4704 (2006.01)

(21) International Application Number:
PCT/US2013/039911

(22) International Filing Date:
7 May 2013 (07.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/644,054 8 May 2012 (08.05.2012) US

(71) Applicant *(for all designated States except BB, US)*: **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, Petach Tikva 49131 (IL).

(71) Applicant *(for BB only)*: **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).

(72) Inventors; and

(71) Applicants *(for US only)*: **LAXER, Avital** [IL/IL]; 26 Ben-Yosef St., Tel-Aviv 6912526 (IL). **ULANENKO, Konstantin** [IL/IL]; Beeri St. 69/1, Netanya 42258 (IL).

(74) Agent: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: N-ETHYL-4-HYDROXYL-1-METHYL-5- (METHYL(2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) -2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE




Figure 1

(57) Abstract: The subject invention provides pharmaceutical compositions Containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1 -methyl-5- (methyl (2, 3,4,5, 6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1, 2- dihydroquinoline- 3 -carboxamide or a salt thereof, compositions containing N-ethyl-4-hydroxyl-1-methyl-5- (methyl (2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1, 2-dihydroquinoline-3-carboxamide and methods of preparing the same.

WO 2013/169746 A3

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
5 December 2013